Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ImPrecise Oversight? Cordis Monitoring Gaps Yield Second Warning Letter

This article was originally published in The Gray Sheet

Executive Summary

J&J Cordis says it is developing more "robust" systems and processes for overseeing clinical studies in response to FDA's warning letter faulting the company for sponsor monitoring lapses in its SAPPHIRE trial
Advertisement

Related Content

Cordis Precise, Guidant Acculink Are First “Approvable” Carotid Stents
Cordis Precise, Guidant Acculink Are First “Approvable” Carotid Stents
J&J Precise Panel Vote Nearly Split On Carotid Disease Subgroup Benefit
J&J Precise Panel Vote Nearly Split On Carotid Disease Subgroup Benefit
Device Firms Struggling With Trial Monitoring Could Receive BIMO Guidance
Cypher Warning Letter Cites Systemic GMP Problems At Multiple Facilities
Advertisement
UsernamePublicRestriction

Register

MT020619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel